Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Interrupting HAART during limited periods of time ("structured treatment interruption : STI")
could entail benefits (better long term tolerance, lower drug-induced viral resistance, lower
cost) but also concomitant risks (lower efficacy, higher drug-induced viral resistance). At
present, the benefit/risk ratio of STI is unclear. Several STI trials are in progress in
industrialised countries. This trial aim at assessing the benefits and risks of two different
STI strategies in West Africa.
Phase:
Phase 3
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis